Use of statins for treatment of familial homozygous hypercholesterolemia: What is the earliest age for initiating statin therapy and what is the maximum dose used in young children.
The dose that is usually mentioned in the pamphlet is the minimal effective dose, in the lowest dose products (if there are several products of different concentrations). For children the minimal dose is usually a tea-spoonful dose (for syrups and suspensions). In some specific medicines we use a graded dropper in ml level, in such cases you've to follow the instructions carefully. In all cases the use of medicinal agents have to be by the instructions of Doctors.
But, why don't you try first by sports and sun, then you may not need to describe statins
The FDA recommends against 80mg daily simvastatin dosage. In patients with the C allele at SLCO1B1 rs4149056, there are modest increases in myopathy risk even at lower simvastatin doses (40mg daily) in pediatric population.
Try all modifiable risk factors without medication first.
I love his book also it is an excellent resourceful one. http://www.drperlmutter.com/about/grain-brain-by-david-perlmutter/
I don't think children should be exposed to any "Statins".
There are other solutions available.
children should receive other options as recommended by prof dr shahid h sheikh .Although occasional children with familial hypercholesteremia may receive upto 40 mg simvastatin as suggested by the former colleague although higher doses may not be safe with statind only affecting 20-40%of effect in LDL -cholesterol .Although newer therapies are being tried for FH even there safety profile is not currently clear like the MTP antagonists like mipoversen and miR 30c antisense oligo nucleotiddes may work out but all are in trial stages.
Thank you Dr. Dr. Kulvinder Kaur.
Hyperlipidemia / Dyslipidemia are neuroinvasive virally induced conditions.
In 2006 I have presented the paper on it in the IMSACON, Lahore, Pakistan.
"World Record in Hyperlipidemia Deterrence in Shortest Time"
82% Reduction in 10 days treatment.
Lowering the viral level, naturally resolves the etiology.
you are welcome prof shahid and i agree lowering the viralload would naturally resolve the etiology as in children the etiology is ifferent from that of adults with obesity or children with FH. and one has to modify treatment according to the aetiology.
Dear Dr. Kulvinder,
The Hypercholesterolemia roots in the disrupted liver's controlling neurons, where thenucleus of those neurons are usually overwhelmed with the continuous Viral RNA proliferation and in turn, the dysfunctional neurons are not able to stop the cholesterol neogenesis process.
Therefore, these neuronal function must be regained from the proliferating neuro invasive viruses. This will stop a big sales of statin mafia. But it will rescue the humanity.
Jalandhar has been the town where my parents grew up and married before partition.
It feels like that I am talking to my family. It is nice.
Have a wonderful day.
Dr. Shahid
I Think In pediatric age group the statins should not be used but if the situation warrants one can use io mg of atorvastatin
In generally speaking, many adult medications can cause side effect, be effective or be ineffective in children because they are administrated in children without proper clinical trials. One of the most common side effects of stain medication is rhabdomyolysis. However, we have to consider the risks and benefits.
but the question is what alternative you have in familial homozygous hypercholesteremiawhich is the question for dosing of statins in children ansd till an alternative like some microRnaS DIRECTLY TARGETING the cause is found one has to continue weighing the risk of rhabdomyolysis with the minimum safe dose of statins with whatever add on agents one can try in the modern day amamentarium like inhibitirs of apoB etc but allof them have some toxivcity in liver and raise transaminases and whether would be safe for children one wonders.
- Badges
- Science topic
- Similar topics
- Chemistry
- Pharmacology
- Medical Pharmacology
- Clinical Pharmacology